Phospho-PGR (Ser400) Antibody

What is the Phospho-PGR (Ser400) Antibody and what does it detect?

Phospho-PGR (Ser400) antibody specifically detects progesterone receptor protein only when phosphorylated at the Serine 400 residue. This phosphorylation is mediated by cyclin-dependent protein kinase 2 (CDK2) and is regulated in response to progestins and mitogenic factors . Unlike general PGR antibodies, phospho-specific antibodies allow researchers to monitor the activation state of the receptor, providing crucial information about signaling dynamics and receptor function in various physiological and pathological contexts.

What applications are suitable for Phospho-PGR (Ser400) Antibodies?

Phospho-PGR (Ser400) antibodies can be utilized in multiple experimental techniques:

These applications allow researchers to investigate phosphorylation status, subcellular localization, and relative abundance of phosphorylated PGR in various experimental conditions .

What controls should be included when using Phospho-PGR (Ser400) Antibodies?

When designing experiments with Phospho-PGR (Ser400) antibodies, several controls are essential:

• Total PGR antibody staining (non-phospho-specific) to determine the ratio of phosphorylated to total receptor

• GAPDH antibody as an internal loading control for normalization

• Negative controls including HRP-conjugated secondary antibodies alone without primary antibodies

• Phospho-peptide blocking experiments to confirm specificity

• Treatment controls (e.g., with and without progestin stimulation)

These controls are critical for result validation and proper data interpretation, especially when comparing phosphorylation status across different experimental conditions.

How should researchers prepare cell samples for Phospho-PGR (Ser400) detection?

Optimal sample preparation for Phospho-PGR (Ser400) detection involves:

• Culture adherent cells until 75-90% confluent (typically 20,000-30,000 cells per well for a 96-well plate)

• For suspension cells, coat plates with 10 μg/ml Poly-L-Lysine before cell seeding

• Apply appropriate treatments (progestins, kinase modulators, etc.) according to experimental design

• Fix cells with 4% formaldehyde for adherent cells or 8% formaldehyde for suspension cells

• Include phosphatase inhibitors in all lysis buffers to preserve phosphorylation status

Rigorous attention to these preparation steps is crucial as phosphorylation states can rapidly change during sample handling, potentially leading to false negative results.

How does CDK2 regulate PGR Ser400 phosphorylation and what are the downstream effects?

CDK2-mediated phosphorylation of PGR at Ser400 serves as a molecular link between cell cycle progression and steroid hormone responsiveness. Research indicates that:

• Elevated CDK2 activity correlates with increased Ser400 phosphorylation

• Expression of cyclin E elevates CDK2 activity and downregulates PGR independently of ligand

• Overexpression of activated mutant CDK2 increases PGR transcriptional activity both in the presence and absence of progestin

• Mutation of PGR Ser400 to alanine (S400A) blocks CDK2-induced PGR activity in the absence of progestin, but not in its presence

• CDK2-induced ligand-independent activation of PGR is inhibited in cells with elevated p27 levels

These findings suggest that Ser400 phosphorylation functions as a regulatory switch that can modulate PGR activity in response to cell cycle signals, with important implications for hormone-responsive cancers with upregulated CDK2.

How can researchers distinguish between specific phospho-PGR (Ser400) signal and non-specific binding?

Distinguishing specific from non-specific signals requires rigorous validation:

• Perform peptide competition assays using phospho-Ser400 peptides versus non-phosphorylated peptides

• Western blot analysis should show a single protein band at the expected molecular weight (approximately 60-62 kDa)

• Compare ELISA results with phospho-peptide versus non-phospho peptide counterparts to confirm specificity

• Use S400A mutant PGR as a negative control to confirm antibody specificity

• Include samples with and without CDK2 activation to demonstrate dynamic regulation of the phosphorylation site

ELISA data demonstrates that Anti-Progesterone Receptor (Phospho-Ser400) antibodies exhibit significantly higher binding to phospho-peptides compared to non-phosphorylated peptides, confirming their specificity for the phosphorylated form of the receptor .

How does Phospho-PGR (Ser400) status change in response to different treatments and physiological conditions?

Phosphorylation of PGR at Ser400 is dynamically regulated by multiple factors:

• Progestin treatment increases Ser400 phosphorylation through direct receptor binding and subsequent conformational changes

• Mitogenic factors enhance CDK2 activity, leading to increased Ser400 phosphorylation even in the absence of progestin

• Cell cycle phase influences phosphorylation levels, with potential increases during S-phase when CDK2 activity is highest

• p27 levels can negatively regulate CDK2 activity and subsequently affect PGR Ser400 phosphorylation status

• Serum starvation and selective CDK inhibitors can reduce phosphorylation levels

Understanding these dynamics is crucial for interpreting experimental results, particularly in complex systems where multiple signaling pathways interact with steroid hormone receptor function.

What role does Phospho-PGR (Ser400) play in nuclear localization and how can this be experimentally measured?

Research indicates that Ser400 phosphorylation is required for ligand-independent, CDK2-induced PR nuclear localization:

• Mutation of Ser400 to alanine (S400A) blocks CDK2-induced nuclear localization in the absence of ligand

• Phosphorylation at Ser400 may induce conformational changes that expose nuclear localization signals

• CDK2-induced nuclear localization of PGR is inhibited in cells with elevated p27 levels

• RNA interference knock-down of p27 can partially restore CDK2-induced ligand-independent PR activation

To experimentally measure these effects, researchers should:

• Perform cellular fractionation followed by Western blotting with phospho-specific antibodies

• Conduct immunofluorescence studies using both phospho-specific and total PGR antibodies

• Utilize GFP-tagged wildtype and S400A mutant PGR to track localization in real-time

• Compare nuclear/cytoplasmic ratios across different treatment conditions and genetic backgrounds

What are the optimal conditions for Phospho-PGR (Ser400) Antibody in Western Blotting applications?

For optimal Western Blot results with Phospho-PGR (Ser400) antibodies:

• Use a 1:1000 dilution for Cell Signaling Technology Phospho-Tpl2 (Ser400) Antibody #4491 or 1:500-1:2000 for other commercial antibodies

• Expected molecular weight is 60-62 kDa

• Include phosphatase inhibitors in all lysis buffers

• Run appropriate positive controls (e.g., cells treated with progestins or heat shock)

• Block membranes with 5% BSA rather than milk (which contains phosphoproteins)

The antibody sensitivity may be limited to detecting transfected levels of protein rather than endogenous levels in some cell types, so experimental design should account for this limitation .

How should researchers design Cell-Based ELISA experiments for Phospho-PGR (Ser400) detection?

For successful Cell-Based ELISA experiments:

• Seed approximately 20,000 adherent cells per well in a 96-well plate

• For suspension cells, pre-coat wells with 10 μg/ml Poly-L-Lysine

• Allow cells to reach 75-90% confluence before treatment

• Fix cells with appropriate formaldehyde concentration (4% for adherent, 8% for suspension cells)

• Include GAPDH antibody controls for normalization

• Perform each condition in duplicate or triplicate for statistical reliability

• Include both phospho-PGR and total PGR antibodies to calculate phosphorylation ratios

Cell-Based ELISA provides the advantage of measuring phosphorylation status in intact cells, preserving subcellular localization information and avoiding artifacts introduced during cell lysis.

What cell types are most appropriate for studying Phospho-PGR (Ser400) function?

When selecting cell models for Phospho-PGR (Ser400) research:

• HeLa cells are commonly used and well-validated (recommended seeding density: 30,000 cells per well)

• Breast cancer cell lines (such as MCF-7, T47D) express endogenous PGR and are physiologically relevant

• COS7 cells are suitable for overexpression studies

• 293 cells respond to heat shock treatment for positive control experiments

• Consider p27 expression levels as they may influence CDK2-dependent phosphorylation

The choice of cell line should reflect the specific research question, with consideration for endogenous PGR expression levels, CDK2 activity, and relevant signaling pathways.

How can researchers quantify and normalize Phospho-PGR (Ser400) data?

Proper quantification and normalization are essential for reliable results:

• For Western blotting:

  • Normalize phospho-PGR signal to total PGR levels

  • Further normalize to housekeeping proteins like GAPDH

  • Use densitometry software for band intensity quantification

• For Cell-Based ELISA:

  • Calculate the ratio of OD values: Phospho-PGR/Total PGR

  • Normalize to GAPDH OD values from the same samples

  • Apply the formula: (Phospho-PGR/GAPDH)/(Total PGR/GAPDH)

• For immunofluorescence:

  • Measure mean fluorescence intensity

  • Calculate nuclear/cytoplasmic ratio

  • Normalize to total PGR staining

Appropriate normalization controls for both technical and biological variation, allowing for more accurate comparisons between experimental conditions.

How should researchers address weak or inconsistent Phospho-PGR (Ser400) signal?

When encountering weak or inconsistent signals:

• Confirm cell treatment conditions effectively activate CDK2 (e.g., stimulation with EGF or heat shock)

• Ensure phosphatase inhibitors are fresh and used at appropriate concentrations

• Optimize fixation time (20 minutes is standard, but may require adjustment)

• Increase antibody concentration or incubation time

• Consider protein enrichment through immunoprecipitation before Western blotting

• Verify antibody lot-to-lot consistency with manufacturer

Phosphorylation events are often transient and can be lost during sample processing, so rapid handling and appropriate inhibitors are crucial for preserving phosphorylation status.

What approaches can investigate the interplay between multiple PGR phosphorylation sites?

To study interactions between Ser400 and other phosphorylation sites:

• Use phospho-mimetic mutations (S→D or S→E) and phospho-resistant mutations (S→A) in combination

• Apply selective CDK2 inhibitors alongside activators of other kinase pathways

• Perform multiplexed detection with different phospho-specific antibodies

• Conduct mass spectrometry analysis to quantitatively assess multiple phosphorylation sites simultaneously

• Develop computational models to predict phosphorylation patterns and functional outcomes

Understanding the hierarchy and interplay between multiple phosphorylation events is critical, as Ser400 phosphorylation may influence or be influenced by modifications at other sites, creating complex regulatory networks.

What are the broader implications of Phospho-PGR (Ser400) research for understanding hormone signaling?

The study of Phospho-PGR (Ser400) has significant implications for understanding steroid hormone receptor biology:

• It demonstrates how cell cycle regulators can directly modulate steroid hormone receptor activity

• Reveals mechanisms for ligand-independent activation of steroid receptors

• Provides insight into potential resistance mechanisms in hormone therapy

• Helps explain context-dependent progesterone receptor function

• May offer new therapeutic targets for hormone-responsive cancers with aberrant CDK2 activity